Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 100%Moderate 0 · 0%High 0 · 0%

Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Sotrovimab may leads to lower serious adverse events compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.27 [0.12, 0.63]
1 study · 868 participants
Low

Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Sotrovimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.87 [0.66, 1.16]
1 study · 868 participants
Low

Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Sotrovimab may leads to lower adverse events: grades 3 and 4 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.26 [0.12, 0.6]
1 study · 868 participants
Low